No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SWTX SpringWorks Therapeutics
- 44.200
- +0.820+1.89%
Close Apr 25 16:00 ET
- 42.000
- -2.200-4.98%
Pre 08:53 ET
3.27BMarket Cap-8582P/E (TTM)
45.195High41.750Low999.79KVolume42.590Open43.380Pre Close44.15MTurnover1.46%Turnover RatioLossP/E (Static)74.06MShares53.92052wk High5.23P/B3.02BFloat Cap18.00052wk Low--Dividend TTM68.43MShs Float96.480Historical High--Div YieldTTM7.94%Amplitude13.600Historical Low44.154Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
Correction to SpringWorks Therapeutics Rating on March 6
JP Morgan raised its price target on SpringWorks to $75.00/share from $74.00/share. "SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by JP Morgan" at 6:49 a.m. ET on March 6 i
SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by HC Wainwright & Co.
SpringWorks Therapeutics Price Target Raised to $74.00/Share From $73.00 by HC Wainwright & Co.
SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan
SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Springworks Therapeutics (SWTX) and Genmab (GMAB)
Comments
Gear up for AACR24!
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
$SpringWorks Therapeutics(SWTX.US$ nice go down so i can get some
JP Morgan analysts believe Ogsiveo's broad label is an outright victory for SpringWorks. They see the drug's global blockbuster potential and notice the company's research into its applicability to certain ovarian tumors and multiple myeloma.
1
1
News
$SpringWorks Therapeutics(SWTX.US$ SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors 1 MINUTE AGO, 6:04 PM EST VIA GLOBENEWSWIRE
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg